Test Price
2,800 AED✅ Home Collection Available
WDR19 Gene Cranioectodermal Dysplasia Type 4 Genetic Test in UAE | 2,800 AED
Executive Summary & Core Metrics
This advanced NGS test provides 99.9% diagnostic sensitivity for cranioectodermal dysplasia type 4 (CED4) through ISO‑accredited processing. Whole‑exon and splice‑site analysis of the WDR19 gene is combined with MLPA confirmation for copy number variants.
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing (Next Generation Sequencing, >100x coverage).
- Premium Logistics: Hospital-Grade Home Collection (8 AM – 11 PM) using ISO Certified Cold-Chain and VIP Mobile Phlebotomy.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance by DHA-licensed genetic counsellor for result interpretation.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The WDR19 full gene analysis uses next‑generation sequencing (Illumina platform, 100x mean coverage) to detect single nucleotide variants, indels, and copy number variants within the coding region and splice sites. Reflex MLPA confirms CNVs. Below is a comparison with typical multi‑gene panel alternatives.
| Feature | Our WDR19 Full Gene Analysis | Closest Alternative (Multi‑Gene Panel) |
|---|---|---|
| Precision | >99.9% sensitivity for SNVs, indels, and CNVs within WDR19 | May miss deep intronic or regulatory variants; CNV detection not guaranteed |
| Methodology | NGS (Illumina, 100x mean coverage) + MLPA confirmation | Targeted NGS panel without reflex MLPA |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks |
| Sample Type | Whole Blood (3 mL EDTA), Extracted DNA, or One Drop Blood on FTA Card | Typically fresh whole blood only |
Physician Insight & Safety Protocols
“A genetic diagnosis of cranioectodermal dysplasia type 4 must always be correlated with comprehensive clinical evaluation by a paediatric clinical geneticist. This result provides critical information for management of renal function, vision, and skeletal growth, but it is not a substitute for ongoing multidisciplinary care. Clinical decisions regarding therapy adjustments should always be made in consultation with the specialist.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Reg. ID: 9294403
Advisory: Medication Warning
Do not discontinue or alter any prescribed medication without first consulting your treating physician. Only the managing clinician can evaluate the risks and benefits of treatment changes based on the genetic findings.
Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Patients currently hospitalised for acute metabolic decompensation or recent major surgery; severe bleeding disorders contraindicating venipuncture. For minors, valid legal guardian consent is mandatory under Federal Decree-Law No. 4 of 2016 on Medical Liability.
- ER Red Flags: If the patient develops new-onset seizures, rapidly increasing head circumference, severe respiratory distress, or acute kidney failure, proceed immediately to the nearest emergency department. These signs may indicate hydrocephalus or rapid disease progression requiring urgent intervention.
Patient FAQ & Clinical Guidance
1. What does the WDR19 gene test detect?
It identifies pathogenic DNA variants in the WDR19 gene that cause cranioectodermal dysplasia type 4 (CED4 / Sensenbrenner syndrome), confirming the clinical diagnosis and guiding targeted management of renal, ophthalmologic, and skeletal complications.
2. Is genetic counselling required before the test?
Yes, a pre‑test genetic counselling session is essential to draw a detailed pedigree, explain possible outcomes, and obtain informed consent, especially for at‑risk family members. This is conducted by a DHA‑licensed genetic counsellor.
3. How does the home collection service work?
A DHA‑licensed phlebotomist arrives at your doorstep between 8 AM and 11 PM, collects the sample under full cold‑chain protocol, and delivers it directly to our ISO‑certified laboratory in Dubai Healthcare City.
UAE Regulatory & Data Privacy Adherence
Your data is protected under Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of ICT in Health Fields. All clinical information is encrypted and accessible only by authorised healthcare professionals. Informed consent follows the Medical Liability Law (Federal Decree‑Law No. 4 of 2016).
Our laboratory is DHA‑licensed (Facility No. 1143) and located at Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | WDR19 Gene Cranioectodermal Dysplasia Type 4 Genetic Test (CED4) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (3 mL EDTA), Extracted DNA, or One Drop Blood on FTA Card |
| Methodology Used | Next Generation Sequencing (Illumina, 100x mean coverage) with MLPA confirmation |
| ICD-10-CM Code | Q87.8 |
| LOINC Code | 98747-9 |
| DHA Facility License & Laboratory Address | DHA License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | Lab: DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians